Tag: dermatological research

Digital + omics = unprecedented target-disease associations

AlmirallShare digital technologies

Almirall, S.A. and the group of Computational Genomics from the Life Sciences Department of the Barcelona Supercomputing Center (BSC), have entered into a research collaboration focused on the identification of new targets to treat dermatological diseases.

The aim of this collaboration is to identify new unprecedented target–disease associations using a number of large scale public omics data sources in combination with the unique expertise and phenomenal technological capabilities of the Barcelona Supercomputing Center (BSC). These capabilities will be used by the BSC to re-analyze existing omics datasets from two dermatological diseases within Almirall focus in order to deliver new target opportunities.

Omics refers to the collective technologies used to explore the roles, relationships, and actions of the various types of molecules and processes that make up the cells of an organism, and have been named as genomics, transcriptomics, proteomics, metabolomics, etc. depending on the family of cellular molecules and processes in each case.

Dr. Jorge Beleta, Research Director, Almirall, commented: “We believe that the world class expertise and capabilities of Dr. Torrents´ group at the Barcelona Supercomputing Center will provide an excellent opportunity to integrate the power of the latest digital and omics technologies into our drug discovery platform”.

At the same time, Dr. David Torrents, leader of the Computational Group from the Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS), stated: “For us, collaborating with companies such as Almirall is a great opportunity to apply our research to specific cases and to go on improving processes and methods based on massive data analysis to speed up drug discovery”.

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed. The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM).

Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life. Total revenue in 2017 was 755.8 million euros and more than 1,830 employees are devoted to Science.

For more information, please visit almirall.com linkedin.com/company/almirall

About Barcelona Supercomputing Center

BSC is the leading supercomputing center in Spain. It specializes in high-performance computing. It has a dual role: providing infrastructure and a supercomputing service for Spanish and European scientists, and generating knowledge and technology to be transferred to society. It is a Severo Ochoa Center of Excellence, a member of the top-level European research infrastructure PRACE (Partnership for Advanced Computing in Europe) and manages the Spanish Supercomputing Network (RES). BSC is a public consortium owned by the Spanish Government Ministry of Science, Innovation and Universities (60%), the Catalan Government Department of Business and Knowledge (30%) and the Polytechnic University of Catalonia (10%).

Almirall + Leo = Unique dermatology research collaboration

AlmirallShare-Open Innovation-dermatological research

The companies aim to develop a painless, minimally invasive skin sampling method to enable more accurate and comprehensive biomarker analysis in clinical trials and exploratory research.

This is the first time two leading dermatology players join forces to advance understanding of skin diseases.


Barcelona, Spain, Ballerup, Denmark, 30th May 2017 – Almirall S.A. and LEO Pharma A/S announced today a unique collaboration that aims to advance understanding of skin diseases by setting a new standard for skin sampling.

The companies aim to develop and clinically validate a painless, minimally invasive skin sampling method that enables accurate and comprehensive biomarker analysis in clinical trials and exploratory research.

The agreement is unique in that it is the first time leading dermatology players join forces in research to advance understanding and treatment of skin diseases.

Eduardo Sanchiz, CEO of Almirall commented: “We are very pleased with this collaboration with LEO Pharma, which will provide the scientific community with new tools to understand and treat skin diseases. This project is another step in gaining a deeper understanding of these pathologies  so that, in the future, we will be able to provide solutions to cover healthcare professionals and patients unmet needs”.

Gitte Aabo, CEO and President of LEO Pharma, said: “We are proud to join forces with Almirall to address the urgent need for a skin sampling method that is painless, minimally invasive and clinically validated. Our unique collaboration has the potential to help patients and indeed the entire scientific community in dermatology as we work towards a common goal of advancing understanding of skin diseases”.

The research  will  be  conducted  at  the  Hospital  Clinic  of  Barcelona  (Spain),  the Technical University of Denmark and the University of Bath (UK). The methodology will be  validated  in selected  patient  populations  and  the final  research  results  will  be published in peer reviewed journals.

 

About Almirall

Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics with the mission of providing valuable medicines and medical devices to you and future generations. Our R&D is focused on Dermatology, with a wide range of programs including key indications. Through our innovative  products, agreements  and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers unmet needs.

Founded in 1943, headquartered in Barcelona,  Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2016, its revenues totalled 859.3 million euros and, with more than 2.000 employees, it has gradually built up a trusted presence across Europe, as well as in the US.

For more information, please visit  www.almirall.com.

 

About LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.

For more information please visit: www.leo-pharma.com.

 

Media contact LEO Pharma

Eva Juul Langlands, eva.langlands@leo-pharma.com 

Tel.: (+45) 41 88 30 94

Media contact: Cohn & Wolfe

Adriana Ibargüen, Adriana.ibarguen@cohnwolfe.com / RebecaRocha, Rebeca.rocha@cohnwolfe.com

Tel.: (+34) 91 531 42 67                                             

Investors & Corporate communication contact: Almirall

Pablo Divasson del Fraile

Tel (+34) 93 291 30 87

 

Disclaimer

This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are “forward-looking statements”. These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Companies. These statements involve risks and uncertainties beyond the Companies’ control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Companies expressly disclaim any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.